Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)2. REPORT TYPE 3. DATES COVERED (From -To) 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER 5b. GRANT NUMBER 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER 5e. TASK NUMBER E-Mail:5f. WORK UNIT NUMBER Mechanisms of KAI1/CD82-Induced Prostate Cancer Metastasis Cynthia Miranti Metastatic prostate cancer kills over 28,000 American men every year. The mechanisms that drive metastasis are poorly understood. We investigated the hypothesis that loss of the metastasis suppressor gene, CD82/KAI1 in primary prostate tumors of genetically engineered mice would be sufficient to induce metastasis.
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTWhile CD82 was sufficient to suppress metastasis of metastatic tumor cells lines and did so by repressing c-Met, the reverse was not true, i.e. loss of CD82 was not sufficient to induce metastasis. This was the case in at least two genetically engineered prostate cancer models. Ongoing studies in different models may yet prove otherwise.Our other hypothesis, that CD82 was suppressing c-Met and invasion through integrins, was proven invalid in these studies. Other tetraspanins that CD82 associates with, i.e. CD9 and CD151 were required to suppress cMet, but not invasion. Thus, these two events must be occurring via different mechanisms. Nonetheless, we are finding several interesting phenotypes in the CD82 null mice which will shed additional light on CD82 function overall and be useful in developing new hypotheses about how CD82 functions as a metastasis suppressor. cell biology, integrins, KAI1/CD82, tetraspanins, metastasis, c-Met, HGF, mouse models cindy.miranti@vai.org 3
INTRODUCTIONProstate cancer is the most frequently diagnosed cancer and the third leading cause of cancer deaths in men in the United States. 1 Death is due to invasion and metastasis beyond the prostate gla...